Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vera Adradas
Observed name:
V. Adradas
Institutions:
Research Institute Hospital 12 de Octubre,
Spanish National Cancer Research Centre,
Hospital Universitario 12 De Octubre,
Universidad de Navarra
Observed institutions:
Research Institute Hospital 12 de Octubre,
Spanish National Cancer Research Centre,
Hospital Universitario 12 De Octubre,
Universidad de Navarra
ORCID:
0009-0008-6774-8888
Observed ORCID:
0009-0008-6774-8888
OpenAlex ID:
A5076643417
PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2023
·
Francisco Exposito
, Miriam Redrado
, et al.
·
Cancer Research
·
102
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
2022
·
Myrto K Moutafi
, Magdalena Molero
, et al.
·
Journal for ImmunoTherapy of Cancer
·
49
PDF
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
2024
·
Melina Peressini
, Rosario Garcia-Campelo
, et al.
·
Clinical Cancer Research
·
19
Forecasting oncogene amplification and tumour suppressor deletion
2025
·
Barbara Hernando
, Angel Fernandez-Sanroman
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
PDF
Data from PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells
2024
·
Francisco Exposito
, Miriam Redrado
, et al.
·
1
Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
2023
·
Melina Peressini
, Rosario Garcia Campelo
, et al.
·
Journal of Clinical Oncology
·
1
Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer
2026
·
Carmen Fernández-Luna
, Javier Baena
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Spatial transcriptomic profiling to identify stroma-based prognostic groups in oncogene-addicted lung cancer.
2026
·
Helena Bote-de Cabo
, Adrian Portillo
, et al.
·
Journal of Clinical Oncology
Abstract 7174: Restoring antitumor immunity and improving immunotherapy outcomes in KRAS-mutant NSCLC through MYC inhibition by OMO-103
2026
·
Íñigo González-Larreategui
, Sílvia Casacuberta-Serra
, et al.
·
Cancer Research
Abstract 3534: Forecasting oncogene amplification and tumor suppressor deletion
2026
·
Barbara Hernando
, Angel Fernandez-Sanroman
, et al.
·
Cancer Research
Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Figure Legends from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Materials and Methods from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Tables from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025
·
Francisco Exposito
, Miriam Redrado
, et al.
173P: Clinical and pathological insights into EGFR-mutated early-stage non-small cell lung cancer (NSCLC): Associations with survival, PD-L1 expression, and second primary neoplasms
2025
·
B. Del Rio
, H. Bote-De Cabo
, et al.
·
Journal of Thoracic Oncology
PDF
P1.06A.05 Assessing Pathologic Response to Neoadjuvant Chemoimmunotherapy for NSCLC: Aligning Current Protocols with Artificial Intelligence
2024
·
E. Conde
, D. Curto
, et al.
·
Journal of Thoracic Oncology
PDF
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC
2024
·
S. Casacuberta Serra
, I. González-Larreategui
, et al.
·
European Journal of Cancer
Supplementary Figure 2 from PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells
2024
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Figure 1 from PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells
2024
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Tables from PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells
2024
·
Francisco Exposito
, Miriam Redrado
, et al.
Supplementary Figure Legends from PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells
2024
·
Francisco Exposito
, Miriam Redrado
, et al.
Show more works
View as search
Works count:
51
Citation count:
173
H-index:
3
I10-index:
3
Year
Topic
Type